Study S001130

A Randomized, Open-Label, Parallel-Arm, Noninferiority Comparison of the Effects of Two Doses of LY2189265 and Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Glimepiride

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT01075282
Acronym: AWARD-2
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: COMPLETED
Enrollment: 810
Start: 2010-02
Primary completion: 2012-05
Lead sponsor: Eli Lilly and Company
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:Insulin Glargine; DRUG:LY2189265; DRUG:Metformin; DRUG:Glimepiride
Results posted: TRUE
Secondary identifiers: OTHER:H9X-MC-GBDB

Registered primary outcomes

Change From Baseline to 52 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c) [Baseline, 52 weeks]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0020285	Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Yu M, Diabetes, obesity & metabolism	2016	Other trial	PMID 26691396 DOI	cites ClinicalTrials.gov:NCT01075282; registry reference DERIVED:26691396
R0025090	Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥65 and <65 years. Boustani MA, Diabetes, obesity & metabolism	2016	Other trial	PMID 27161178 DOI	cites ClinicalTrials.gov:NCT01075282; registry reference DERIVED:27161178
R0015848	Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2). Giorgino F, Diabetes care	2015	Randomized trial	PMID 26089386 DOI	cites ClinicalTrials.gov:NCT01075282; registry reference DERIVED:26089386